Award
NIH Reporter #3U19CA264512-05S1
Tasquinimod as an adjunct to immunotherapies administered peri-operatively
Recipient
Not specified
Award Amount
$680,856.00
Ceiling
$680,856.00
Awarded
September 18, 2026
Identifier
3U19CA264512-05S1
Research grant awarded by the National Cancer Institute to develop tasquinimod as an adjunct immunotherapy for glioblastoma, including phase I and preclinical studies to enhance immunotherapy efficacy.
Description
This is a research grant project focused on developing tasquinimod as an adjunct immunotherapy for glioblastoma, with a focus on controlling cerebral edema and enhancing immunotherapy efficacy. The project involves a phase I safety and feasibility study, preclinical in vivo studies, and aims to support future clinical trials.